1. Home
  2. CAPR vs AREN Comparison

CAPR vs AREN Comparison

Compare CAPR & AREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • AREN
  • Stock Information
  • Founded
  • CAPR 2005
  • AREN 2016
  • Country
  • CAPR United States
  • AREN United States
  • Employees
  • CAPR N/A
  • AREN N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • AREN Medical/Dental Instruments
  • Sector
  • CAPR Health Care
  • AREN Health Care
  • Exchange
  • CAPR Nasdaq
  • AREN Nasdaq
  • Market Cap
  • CAPR 322.7M
  • AREN 305.8M
  • IPO Year
  • CAPR N/A
  • AREN N/A
  • Fundamental
  • Price
  • CAPR $8.43
  • AREN $6.34
  • Analyst Decision
  • CAPR Strong Buy
  • AREN Strong Buy
  • Analyst Count
  • CAPR 8
  • AREN 1
  • Target Price
  • CAPR $24.75
  • AREN $10.00
  • AVG Volume (30 Days)
  • CAPR 2.7M
  • AREN 174.1K
  • Earning Date
  • CAPR 08-06-2025
  • AREN 08-18-2025
  • Dividend Yield
  • CAPR N/A
  • AREN N/A
  • EPS Growth
  • CAPR N/A
  • AREN N/A
  • EPS
  • CAPR N/A
  • AREN 0.16
  • Revenue
  • CAPR $17,363,588.00
  • AREN $128,781,000.00
  • Revenue This Year
  • CAPR $453.92
  • AREN $275.98
  • Revenue Next Year
  • CAPR N/A
  • AREN N/A
  • P/E Ratio
  • CAPR N/A
  • AREN $26.54
  • Revenue Growth
  • CAPR N/A
  • AREN N/A
  • 52 Week Low
  • CAPR $3.52
  • AREN $0.56
  • 52 Week High
  • CAPR $23.40
  • AREN $10.05
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 38.63
  • AREN 51.84
  • Support Level
  • CAPR $6.26
  • AREN $5.62
  • Resistance Level
  • CAPR $7.28
  • AREN $6.57
  • Average True Range (ATR)
  • CAPR 0.69
  • AREN 0.48
  • MACD
  • CAPR -0.04
  • AREN -0.00
  • Stochastic Oscillator
  • CAPR 10.28
  • AREN 62.93

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

Share on Social Networks: